Related Experiment Video

Updated: May 27, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

The potential for crizotinib in non-small cell lung cancer: a perspective review

Yung-Jue Bang1

  • 1Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea.

Therapeutic Advances in Medical Oncology
|November 16, 2011
PubMed

Insights

Anaplastic lymphoma kinase (ALK) gene rearrangements drive cancer growth. Crizotinib effectively treats ALK-positive non-small cell lung cancer (NSCLC), with ongoing research into resistance mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Tyrosine kinases regulate critical cell signaling pathways.
  • Dysregulated tyrosine kinase signaling, particularly involving anaplastic lymphoma kinase (ALK), drives oncogenesis.
  • ALK gene rearrangements are implicated in non-small cell lung cancer (NSCLC) and other malignancies.

Purpose of the Study:

  • To review the discovery of the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion oncogene.
  • To discuss the identification of various ALK gene rearrangements in NSCLC.
  • To summarize the efficacy of crizotinib in treating ALK-positive NSCLC and explore future directions.

Main Methods:

  • Literature review focusing on ALK gene rearrangements and targeted therapies.
  • Analysis of studies detailing the EML4-ALK fusion and its oncogenic role.
  • Examination of clinical trial data on crizotinib in ALK-positive cancers.

Main Results:

  • The EML4-ALK fusion was identified as a significant oncogenic driver.
  • Multiple ALK gene rearrangements are recognized in NSCLC.
  • Crizotinib demonstrated efficacy in patients with ALK-positive NSCLC.

Conclusions:

  • ALK rearrangements are key oncogenic drivers in specific cancers.
  • Crizotinib is an effective targeted therapy for ALK-positive NSCLC.
  • Further research is needed to optimize crizotinib treatment and overcome resistance mechanisms.
Keywords:
anaplastic lymphoma kinasecarcinomacrizotinibnon-small cell lung cancertyrosine kinase inhibitor

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...